Business Wire

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Sun Journal

Injection, infusion and medication: Demystifying osteoporosis treatments

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone ...
Everyday Health on MSN

How to plan for successful home SCIg self-administration for primary immunodeficiency

Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...
STAT

Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show

A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler, under-the-skin injection is equally effective as the currently approved intravenous infusion, according to study ...
Nasdaq

Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat ...

-- The AGILE trial is designed based on patient and clinician input and part of Horizon’s continued investment to impact the KRYSTEXXA patient experience -- DUBLIN--(BUSINESS WIRE)-- Horizon ...